The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Now approved for both acute and chronic HCV in adults and children aged 3 and above
Ranks among the top 15% companies globally
Subscribe To Our Newsletter & Stay Updated